NewsBenzingaCerenome Completes Enrollment In Phase 2 ReSPECT-GBM Trial Of REYOBIQ In Recurrent Glioblastoma; Topline Data Expected Mid-2027 Cerenome Completes Enrollment In Phase 2 ReSPECT-GBM Trial Of REYOBIQ In Recurrent Glioblastoma; Topline Data Expected Mid-2027 Benzinga 2026.10.29 12:24 (GMT+0) Open on Benzinga Other news T1 Energy Stock Plunges: What's Going On? Why Nvidia Is Falling Tuesday: Jensen Huang’s Comeback Statement, Congress Hearings, and AI Risks General Motors Plans 20% Boost In Robotics As Factory Costs Rise Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies 'Nvidia stopped disclosing Singapore sales as revenues hit $104B' -FT Nike CEO Says Co Aims To Double The Units Of Product Created In Under 14 Months By FY31